(Q37685684)

22 August 2017

1 reference

title

Dopamine receptor agonists in the treatment of advanced Parkinson's disease (English)

1 reference

22 August 2017

0 references

1 reference

Fabrizio Stocchi

1

0 references

publication date

1 December 2009

1 reference

Parkinsonism and Related Disorders

22 August 2017

published in

1 reference

22 August 2017

volume

15 Suppl 4

1 reference

22 August 2017

page(s)

S54-7

1 reference

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Levodopa: why the controversy?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Emerging therapies in the pharmacological treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

1 reference

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Predictive reward signal of dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Unilateral dopamine denervation blocks corticostriatal LTP

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Dual dopamine agonist treatment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Pathological gambling in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Compulsive eating and weight gain related to dopamine agonist use.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Sleepiness in Parkinson's disease: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Subcutaneous apomorphine in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

Use of apomorphine in Parkinson’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970836-3

7 January 2021

10.1016/S1353-8020(09)70836-3

Identifiers

DOI

1 reference

22 August 2017

1 reference